asked in 社會與文化語言 · 1 decade ago

請歷害的人幫我翻譯成中文(給予20點)

標題:Biopharmaceutical drug discovery using novel protein

scaffolds

Introduction

Biopharmaceuticals (i.e. polypeptides or proteins that can

be manufactured and delivered for safe and efficacious

treatment of human disease) represent a major part of the

drug development pipeline across the pharmaceutical

industry. Today, there are more than 300 distinct biopharmaceuticals

in clinical trials for various disease indications

including cancer, Alzheimer’s disease and chronic

inflammation [1]. Additional clinical trials to test biopharmaceuticals

are being initiated at an increasing rate. This

surge of interest has been driven by the success of major

biotechnology products such as Etarnecept, Rituximab

and Epoetin Alfa. In 2005 alone, biotechnology products

totalled revenues of $50 billion [2]. Yet, biotechnology as

an industry was launched merely 30 years ago. Growth in

the industry is projected to be around 20%, driven primarily

by the launch of several new monoclonal antibody

products now in the late stages of clinical evaluation [3].

Their high affinity and target specificity combined with

therapeutic efficacy and safety have made monoclonal

antibodies a product format of choice across diverse

disease indications, including cancer and chronic inflammatory

disorders.

Update:

希望翻通順一點的

3 Answers

Rating
  • SP
    Lv 5
    1 decade ago
    Favorite Answer

    生物製藥藥物發現使用異常蛋白質結構

    介紹

    生物製藥(亦就是能被製造且藥效安全和有效治療人類疾病的多胜肽鏈或蛋白質)代表製藥工業藥物發展管道(史)。今天有超過300種明確的生物製藥針對各種不同的疾病包括癌症,阿茲海默症和慢性發炎進行臨床實驗中(1)。附加臨床實驗以測試生物製藥正開始逐漸增加比率。由於主要生物科技產品像是 Etarnecept, Rituximab及 Epoetin Alfa的成功造成對此工業的興趣湧現。單就2005年,生物科技產品收入達美金五百億(2). 而生物科技產業不過30年前開始。由於受到數種新的單細胞株抗體產品已經進入最後臨床試驗階段,該產業預估成長率約20%(3)。由於單細胞株抗體的高親和力及目標專一性,加上療效與安全,使得本產品成為數種不同病徵的選擇,包括癌症和異常慢性發炎。

    Source(s): 自己囉
  • Anonymous
    6 years ago

    到下面的網址看看吧

    ▶▶http://qoozoo09260.pixnet.net/blog

  • 1 decade ago

    生物製藥藥物發現使用小說蛋白質

    鷹架

    介紹

    生物製藥(也就是 polypeptides 或蛋白質哪一能被製造而且為保險箱被遞送和有效的人類疾病的治療)代表主要部份那橫過下藥發展管道那藥學的工業。 今天,有更多的超過 300 清楚的生物製藥

    在臨床實驗中為各種不同的疾病指示包括癌症,阿茲海默症和慢性的怒火

    〔1]. 另外的臨床實驗測試生物製藥正在逐漸增加的比率被開始。 這興趣的湧現已經被主修科目的成功驅使生物科技產品,像是 Etarnecept, Rituximab and Epoetin Alfa。 在 2005 年孤獨的,生物科技產品總計$五百億

    〔2]. 然而,生物科技當做一種工業被 30 年前只發射。 生長在工業被計畫是大約 20%, 受到驅策的主要地被一些新的單細胞繁殖的抗體的發射現在在臨床評估〔3] 的遲階段的產品.他們的高的密切關係和目標特徵結合治療的效能和安全已經做單細胞繁殖的抗體橫過的一個選擇的產品格式不同的疾病指示,包括癌症和慢性的激動的混亂。

Still have questions? Get your answers by asking now.